SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Gufic Biosciences - Quaterly Results

30 May 2025 Evaluate
The revenue for the March 2025 quarter is pegged at Rs. 2050.20 millions, about 5.14% up against Rs. 1949.94 millions recorded during the year-ago period.The Company to register a -60.22%  fall in the net profit for the quarter ended March 2025.Operating Profit reported a sharp decline to 270.23 millions from 351.09 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 2050.20 1949.94 5.14 8198.06 8066.66 1.63 8198.06 8066.66 1.63
Other Income 3.83 8.81 -56.53 36.15 21.77 66.05 36.15 21.77 66.05
PBIDT 270.23 351.09 -23.03 1386.03 1480.48 -6.38 1386.03 1480.48 -6.38
Interest 84.00 36.47 130.33 231.12 153.60 50.47 231.12 153.60 50.47
PBDT 186.23 314.62 -40.81 1154.91 1326.88 -12.96 1154.91 1326.88 -12.96
Depreciation 78.43 43.42 80.63 210.64 170.17 23.78 210.64 170.17 23.78
PBT 107.80 271.20 -60.25 944.27 1156.71 -18.37 944.27 1156.71 -18.37
TAX 28.05 70.73 -60.34 244.95 295.36 -17.07 244.95 295.36 -17.07
Deferred Tax 25.12 -2.27 -1206.61 57.51 31.65 81.71 57.51 31.65 81.71
PAT 79.75 200.47 -60.22 699.32 861.35 -18.81 699.32 861.35 -18.81
Equity 100.28 100.28 0.00 100.28 100.28 0.00 100.28 100.28 0.00
PBIDTM(%) 13.18 18.01 -26.80 16.91 18.35 -7.88 16.91 18.35 -7.88

Gufic Biosciences Share Price

306.05 4.85 (1.61%)
13-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1652.00
Dr. Reddys Lab 1235.20
Cipla 1211.30
Zydus Lifesciences 923.10
Lupin 2312.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×